Investor Insight
Ave Maria Biotech, Inc. (AMB) was conceived as a direct response to the global health vulnerabilities exposed by the COVID-19 outbreak. The Company’s flagship device, the BD-500, offers real-time detection of airborne viruses and other pathogens, empowering businesses, healthcare facilities, the military, and public spaces to take immediate action, based on accurate data. With over 100 working prototypes, an EU patent, and a series of certifications from labs in the EU, the Company has just executed a Cooperative Research and Development Agreement (“CRADA”) with the U.S. Army's Development Command Chemical Biological Center (“DEVCOM CBC”). This partnership will not only validate AMB’s technology from a U.S. perspective but also position the Company for robust growth within its target verticals.
AMB is currently seeking a Series A capital injection to facilitate its CRADA verification testing with the U.S. Army and to underpin its operational standup expenditures. This will include the initiation of the Company's sales and manufacturing operations.
INVESTMENT HIGHLIGHTS
Innovative Technology:
The first airborne virus detection device of its kind, the BD-500 uses advanced photonics-based technology to detect airborne viruses as small as 3nm-30μm, a range that includes the size of airborne viruses such as COVID-19. This device has been designed to deliver detection results in under five minutes, allowing for rapid and informed responses.
Broad Application Potential:
The BD-500's design caters to a wide array of environments, from safeguarding military installations to enhancing health security on cruise ships. Its versatility addresses a clear and present demand for heightened health security in communal settings, especially in a world still grappling with the aftermath of a pandemic.
Market Timing:
Launching the BD-500 comes at a critical juncture when the world is acutely aware of the need for proactive health solutions. The aftermath of COVID-19 has underscored the importance of such technologies, placing AMB in a position to meet a timely and critical demand.
Efficiency & Data-Driven Interventions:
The BD-500's real-time data capability is its cornerstone, enabling establishments to act based on immediate insights. This is particularly crucial for environments like military bases, where force protection is paramount, and nursing homes, where resident safety is a top priority.
Intellectual Property & Competitive Moat:
AMB's secured European patent for the BD-500 provides a layer of protection against potential
competitors. As AMB progresses through the U.S. patent process, this intellectual property serves as a foundation for its market position and appeal to potential partners.
Solid Growth Trajectory:
With a clear vision, a strong leadership team, and a unique product in the BD-500, AMB is poised for rapid and sustained growth. The company's focus on quick wins in initial target markets, combined with the potential for expansion into new sectors and geographies, underscores its long-term vision and commitment to industry leadership.
Financial Advisor
James Mendelsohn - Proximo Capital Founder
"Ave Marie Biotech has engaged Proximo Capital to assist in engaging and assisting investors. Currently, AMB is in an initial funding round and has engaged Proximo Capital to gather and coordinate investment strategies.
Proximo Capital is a boutique investment advisory firm focused on transaction work in the middle market. The firm is led by its founder James Mendelsohn, who has a long career in financial services, fintech, and strategy consulting."
If you are interested in our opportunity, please contact James Mendolsohn at james@proximocapital.com for more information. Their website is www.proximocapital.com.
